natgillin/translations-raw huggingface dataset:
or, if desired, converting compounds of formula (I) into each other following art-known transformations, and further, if desired, converting the compounds of formula (I), into a pharmaceutically acceptable acid addition salt by treatment with an acid, or into a pharmaceutically acceptable base addition salt by treatment with a base, or conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; and, if desired, preparing stereochemically isomeric forms or N -oxide forms thereof. 
ili, ako se želi, pretvaranje spojeva formule (I) u drugi slijedeći u struci poznate transformacije, te nadalje, ako se želi, pretvaranje spojeva formule (I), u farmaceutski prihvatljivu kiselu adicijsku sol obradom s kiselinom, ili u farmaceutski prihvatljivu baznu adicijsku sol obradom s bazom, ili obrnuto, pretvaranje oblika kisele adicijske soli u slobodnu bazu obradom s lužinom, ili pretvaranje bazne adicijske soli u slobodnu kiselinu obradom s kiselinom; te ako se želi, pripremu stereokemijskih izomernih oblika ili njihovih oblika N-oksida.
Formula 38 (41.37 g, 52.5 mmol) was dissolved in DCM (500 mL) at room temperature. 
Formula 38 (41.37 g, 52,5 mmol) je bila otopljena u DCM (500 mL) na sobnoj temperaturi.
said process comprising reacting a protected 1-acetyl-glycose with a compound having formula II: wherein R1 is as defined above in the presence of a Lewis acid and an organic base, removing the protecting groups from the glycosyl moiety; and obtaining compounds having formula I. 
Formula I u kojoj - Ry jest metoksi- ili metiltiolna skupina, - Ro je ostatak O-glikoziloksi, naznačen time da postupak obuhvaća reakciju zaštićenog 1-acetil-monosaharida sa spojem formule II: u kojoj je Ry kao što je gore definirano, nakon čega slijedi uklanjanje zaštitnih skupina šećernog ostatka.
As can be seen in FIGS. 6A–C, most of system 10 can be integrated into a relatively compact single housing 200 that would be relatively easy to mount, even in sometimes cramped interior spaces of a vehicle or implement. 
Kao što se vidi na slikama 6A-C, najveći dio sustava 10 može se integrirati u jedno jedino, relativno kompaktno kućište 200 koje se može relativno lako ugraditi, čak i u neki put pretrpane unutarnje prostore nekog vozila ili stroja.
Another aspect of the invention relates to a composition comprising one or more lactic acid bacterial strains as described above and a pharmaceutically acceptable excipient, carrier or diluent. 
Pripravak naznačen time da sadrži jedan ili više bakterijskih sojeva mliječne kiseline prema zahtjevu 1 i farmaceutski prihvatljiv ekscipijent, nosač ili sredstvo za otapanje.
X represents two hydrogen atoms; and/or 
X predstavlja dva atoma vodika; i/ili
The sealing material can have a thickness of 0.3mm to 2.5mm, preferably 0.5mm to 2mm. 
Materijal za brtvljenje može imati debljinu od 0.3 mm do 2.5 mm, poželjno 0.5 mm do 2 mm.
The receiver of claim 13, wherein the L1 signaling information has data slice ID information that identifies the data slice. 
Prijamnik iz patentnog zahtjeva 13, pri čemu informacija signaliziranja L1 ima ID informaciju podatkovnog Teza koja identificira podatkovni rez.
A pharmaceutically acceptable liquid composition having a pH of about 9.1 to about 9.8 at 25° C., comprising: 
Farmaceutski prihvatljiv tekući sastav iz zahtjeva 1, naznačeno time da spomenuti sastav ima pH vrijednost od 9,2 do 9,8 na 25*C.
An isolated IL-23p19 antibody, comprising the light chain variable region of claim 8 and a heavy chain variable amino acid sequence of SEQ ID NO:3. 
(11) varijabilnu sekvencu aminokiselina laganog lanca SEQ ID NO: 38 1 varijabilnu sekvencu aminokiselina teškog lanca SEQ ID NO: 33. 4.
Method in accordance with claim 1; characterised in that the stage in which the distribution agent is added includes a proportion by weight of emulsifier that is less than or equal to 2% of the total weight of the package of microwaveable kernels of corn before the kernels are popped. 
Postupak u skladu s patentnim zahtjevom 1; naznačen time što se sredstvo za raspodjeljivanje dodaje u težinskom udjelu emulgatora manjem od ili jednakom 2 % od ukupne težine pakiranja zrna za kokice koje se može peći mikrovalovima dok zrna ne puknu; te što je težina lecitina manja od ili jednaka 0,13 % od ukupne težine pakiranja zrna za kokice koje se može peći mikrovalovima dok zrna ne puknu.
FIELD OF THE INVENTION The invention encompasses methods for isolating and purifying pravastatin from reactions conducted in aqueous fermentation broths. 
Područje izuma Izum obuhvaća metode izolacije i pročišćavanja pravastatina iz reakcija koje se provode u vodenim fermetacijskim bujonima.
The method according to claim 20, wherein said at least one ventilation duct extends within a first shaft extending along a wall of the module. 
Postupak sukladno zahtjevima 6 i 8, pri čemu se navedeni barem jedan ventilacijski otvor (16) pruža unutar prvog otvora za tehničke instalacije.
Panel (1, 42, 43, 46, 53, 57) according to one of the foregoing claims, wherein the first locking element (23, 64) is positioned at a lower level than the upward aligning edge (19b, 61b) of the upward tongue (19, 61). 
Ploča (1, 42, 43, 46, 53, 57) u skladu s jednim od prethodnih patentnih zahtjeva, pri čemu je prvi element zaključavanja (23, 64) postavljen na nižoj razini od gornjeg naliježućeg ruba (19b, 61b) na gore usmjerenog jezika
The vaccine according to claim 23, wherein: the monosaccharide is one or more selected from the group consisting of allose, altrose, glucose, mannose, gulose, idose, galactose, talose, psicose, fructose, sorbose, tagatose, arabinose, ribose, xylose, lyxose, ribulose, xylulose and inositol; 
Adjuvant sukladno patentnom zahtjevu 7, naznačen time što • monosaharid je jedan ili više odabranih iz skupine koja se sastoji od aloze, altroze, glukoze, manoze, guloze, idoze, galaktoze, taloze, psikoze, fruktoze, sorboze, tagatoze, arabinoze, riboze, ksiloze, liksoze, ribuloze, ksiluloze i inozitola;
reacting the compound of formula III with an electrophilic bromine source to obtain a compound of formula IV: 
€) reakcija formule M1 s elektrofilnim izvorom broma, kao što je N-bromsukcinimid ili brom Br,, da se dobije spoj formule IV:
The device according to claim 1, wherein the perforated sheet comprises a plurality of oval shaped holes. 
Uređaj sukladno zahtjevu 1, gdje perforirani list sadrži veći broj ovalno oblikovanih rupa.
Suspension concentrate according to any of the previous claims 1 to 8, comprising expressed by weight based on the total weight of the composition: to 55% dodine particles, 
Koncentrat otopine u skladu s bilo kojim od prethodnih patentnih zahtjeva 1 do 5, sadrži izraženo masom na temelju ukupne mase sastava:
A method for treating or preventing pain in a patient comprising administering to the patient a therapeutically effective amount of an oligonucleotide decoy of claim 1, wherein the oligonucleotide decoy comprises a transcription factor binding site, and wherein said transcription factor binding site binds to transcription factor CEBP. 
Oligonukleotidna zamka prema zahtjevu 10 ili farmaceutski sastav prema zahtjevu 11, naznačen/a time, da se upotrebljava u postupku liječenja bolova ili upravljanja bolovima kod pacijenta, gdje taj postupak obuhvaća davanje navedenom pacijentu terapeutski učinkovitu količinu oligonukleotidne zamke.
The pharmaceutical composition for use according to any of claims 7 - 9, and at least one other active ingredient, preferably a chemotherapeutic active ingredient, for simultaneous, separate or sequential administration. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 14 i najmanje jedan drugi aktivni sastojak, po mogućnosti kemoterapijski aktivni sastojak, naznačeni time što su namijenjeni istodobnoj, odvojenoj ili uzastopnoj primjeni.
The most characteristic peaks are at 9.6 ° and 26.8 °. 
Najkarakterističnije vršne vrijednosti su na 9,6 * i 26,8 *.
wherein, when the bistable portion is in the second stable form, the upper cap closure portion engages with the upper open end of the dispenser cap to close the dispenser cap; 
Dispenzer u skladu sa bilo kojim prethodnim patentnim zahtjevom, gdje gornja površina poklopca (91) dispenzera sadrži sredstva (101) za ograničavanje za sprječavanje rotacije uređaja (120) za zatvaranje poklopca kada je u drugom stabilnom obliku.
The temperature of the WFI was superior to 60° C. The circulation loop flow was set at 583 l·h−1kg−1during 10 min. 
Temperatura WFI-a je bila veća od 60 "C. Kružni cirkulacijski protok je bio podešen na 583 Ih".kg" tijekom 10 min.
bus bars attached at a first end to the surge suppression devices and a second end configured to plug into connectors located on a printed circuit board mounted in one of the first and second surge suppression units. 
uređaje za zaštitu od prenapona (100); i sabirnice (430, 742) s prvim krajem konfiguriranim za pričvršćivanje na jedan od uređaja za zaštitu od prenapona i drugim krajem konfiguriranim za spajanje na priključke (406, 582), koji se nalaze na tiskanoj ploči.
Arithmetic means of PK parameters of the human subject 
Datum objave europskog patenta:
The method of claim 1, wherein said culture is not supplemented with additional components over the course of producing said TNFR-Ig. 
Postupak prema Zahtjevu 1, naznačen time, što se spomenutoj kulturi ne dodaju komponente suplemenata tijekom trajanja proizvodnje spomenutog TNFR-Ig.
The compound for use of any of claims 1-10, wherein the cancer is Kaposi's sarcoma, gynecologic sarcoma, soft tissue sarcoma, resected high-risk soft tissue sarcoma or leiomyosarcoma. 
Spoj za uporabu prema bilo kojem od zahtjeva 1-10, naznačen time da hemoglobinatija ili srodni poremećaj je hemoglobinopatija ili anemija srpastih stanica.
administering to a patient having sickle cell disease a therapeutically effective amount of a chemically modified heparin having an antifactor IIa activity and an antifactor Xa activity, wherein the antifactor IIa activity is less than 10 IU/mg and the antifactor Xa activity is up to 10 IU/mg, the chemically modified heparin having a weight average molecular weight from about 6.5 to about 9.5 kDa, wherein the chemically modified heparin comprises polysaccharide chains having: 
HR P20180726 T1 PATENTNI ZAHTJEVI Kemijski modificiran heparin za upotrebu u liječenju bolesti srpastih stanica, pri čemu kemijski modificiran heparin ima aktivnost antifaktora Ila manju od 10 IU/mg, aktivnost antifaktora Xa do 10 IU/mg i prosječnu molekularnu masu od 6,5 do 9,5 kDa, naznačen time da polisaharidni lanci:
a second cog wheel (22) mobile in rotation (R 2) in relation to the support (2) around a second axis (A 2); 
- < drugi zupčanik (22) koji se okreće (R2) u odnosu na nosač (2) oko druge osovine (A2); u kojem:
Dosage form according to claim 5, which contains an amount of pantoprazole magnesium dihydrate, which corresponds to 80 mg of pantoprazole (free acid). 
Dozimni oblik prema zahtjevu 5, naznačen time, da sadrži jednu količinu pantoprazol magnezij dihidrata, koja odgovara za 80 mg pantoprazola (slobodna kiselina).
The chimeric human/mouse MHC I polypeptide of claim 13, wherein the mouse MHC I polypeptide is selected from the group consisting of H-2K, H-2D and H-2L and wherein the human HLA class I polypeptide is optionally selected from the group consisting of HLA-A, HLA-B, and HLA-C. 
Kimerni ljudski/ne-ljudski, životinjski MHC-I-polipeptid prema zahtjevu 13, naznačen time, da glodarski MHCI-polipetid je mišji MHC-I-polipetid koji je odabran iz skupine koja se sastoji od H-2K, H-2D i H-2L, te time, da je ljudski polipeptid HLA-razreda I opcionalno odabran iz skupine koja se sastoji od HLA-A, HLA-B i HLA-C.
comprising the operation step in which climatic values of the outer environment from which air is absorbed are measured by means of at least one sensor (261) connected to said control unit (260), 
- koji sadrži korak postupka u kojem klimatske vrijednosti vanjske okoline iz koje se zrak apsorbira, mjere uz pomoć najmanje jednog senzora (261) priključenog na spomenutu upravljačku jedinicu (260),
The mini gastrin analogue PP-F11 according to claim 1 or 2, wherein X stands for a nanoparticle or a liposome which have a diagnostic function (e.g. optical active or MRI contrast agent) or which have therapeutic function by themselves or are loaded with an active compound. 
Analog mini-gastrina PP-F11, prema zahtjevu 1 ili 2, naznačen time, da X predstavlja nanočestice ili liposome koji imaju dijagnostičku funkciju (primjerice optički djelotvorno sredstvo ili MRI kontrastno sredstvo) ili koji imaju terapeutsku funkciju sami po sebi ili su napunjeni s djelotvornim spojem.
In that respect the one or more carrier frameworks is such that there is sufficient space for at least one adult between the junction region and the cover tarpaulins which are placed on the carrier framework. 
- jedan ili više prstenastih nosača za nošenje cerade za pokrivanje ili jedne od cerada za pokrivanje, pri čemu između zone utjecaja i cerade za pokrivanje postoji dovoljno prostora za najmanje jednu odraslu osobu, naznačen time što ima
Then the plate (3) is inserted inside the collar (2) and fixed with the screws (8), with the optional frame (9), as shown in Figures 3 and 4 and Figures 7 and 8, respectively. 
Tada se umetne ploča (3) u okvir (2) i učvrsti s vijcima (8), i po želji s okvirom (9), kao stoje prikazano na slikama 3 i 4 odnosno na slikama 7 i 8.
a second heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 and SEQ ID NO:99, and a second light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 and SEQ ID NO:4. 
drugi teški lanac koji obuhvaća aminokiselinsku sekvencu odabranu iz skupine koju čine SEQ ID NO:5, SEQ ID NO:97, SEQ ID NO:98 i SEQ ID NO:99, i drugi laki lanac koji obuhvaća aminokiselinsku sekvencu odabranu iz skupine koju čine SEQ ID NO:1, SEQ ID NO:96, SEQ ID NO:3 i SEQ ID NO:4.
X is C1-6alkanediyl optionally substituted with from 1 to 3 C1-6alkyl groups. 
X je Cisgalkandiil, izborno supstituiran s 1 do 3 C, galkilne skupine.
WO 99/58253 discloses a system for applying a biologically active or chemical substance to a relatively large volume of crop, comprising a nozzle positionable near the agricultural crop, the nozzle being positioned at one end of a fluid conduit, a receiver connected to the fluid conduit to receive a container of biologically active or chemical substance, a pump to deliver a mixture of water and biologically active or chemical substance to the conduit at a rate proportional to operation of the pump with the spray nozzle positioned along a belt conveyor. 
WO 99/58253 opisuje sustav za nanošenje biološki aktivne ili kemijske supstance na relativno veliku količinu usjeva, koji se sastoji od mlaznice koja je smještena u blizini poljoprivrednih usjeva, mlaznica je postavljena na jednom kraju cjevovoda fluida, nosača koji je povezan sa cjevovodom fluida koji prima posuda s biološki aktivnom ili kemijskom supstancom, pumpe za maksimalno dostavljanje vode 1 biološki aktivne ili kemijske supstance u cjevovod brzinom proporcionalnom radu pumpe s mlaznicom za stvaranje spreja, smještenom duž trake transpotera.
The ski boot according to one or more of the preceding claims, characterized in that said fourth screw or rivet (55) is slidably positionable inside second slots (57) provided on said base of said buttress element (5) and connected to second cylinders (56) themselves. 
Cipela za skijanje prema zahtjevu 21, naznačena time, da se četvrti vijak ili zakovica (55) može klizno namjestiti unutar drugih raspora (57) postavljenih na spomenutoj osnovici potpornog elementa (5) i spojenih sa samim drugim cilindrima (56).
A castable refractory material for use in the manufacture of refractory products, wherein the castable refractory material includes fused silica, ceramic fibre, microsilica and a bonding material comprising colloidal silica. 
Vatrostalni materijal koji se može izlijevati namijenjen primjeni u proizvodnji vatrostalnih proizvoda, pri čemu vatrostalni materijal koji se može izlijevati sadrži topljeni silicij-dioksid, keramička vlakna, mikro silicij-dioksid i vezivni materijal koji sadrži koloidni silicij-dioksid.
A compound having the general formula I wherein: 
Spoj s općom formulom I [image], naznačen time što:
A dispiro 1,2,4-trioxolane selected from the group consisting of compounds of formula (I) Wherein R selected from: and their pharmaceutically acceptable salts. 
Dispiro-1,2,4-trioksolan izabran iz grupe koja se sastoji od spoja formule (I) pri čemu je R izabran od: Poe pa #
The oral composition of item 37, wherein the cholesterol lowering agent comprises a bile acid sequestrant (BAS), a statin, ezetimibe, alpha-Linoleitic acid, omega-3,6,9, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), fibrates, soluble fibre, polyphenol, gama-oryzanol hesperetin metabolite, phytochemical, other probiotic, psyllium, phytosterol, phytostanol, vitamin, antioxidant or antibiotic 
(c) agens za smižavanje kolesterola, opcionalno sekvestrant žučnih kiselina (BAS), statin, ezetimib, alfa-linoleitična kiselina, omega-3,6,9, eikozapentaenoična kiselina (EPA), dokozaheksaenoična kiselina (DHA), fibrati, topljiva vlakna, polifenol, metabolit gama-orizanol hesperetina, fitokemikalija, drugi probiotik, psilij, fitosterol, fitostanol, vitamin, antioksidans ili antibiotik;
In certain such embodiments the composition comprises at least about 80% (by wt) polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000. In certain embodiments, the present invention is directed to a solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation, the extended release matrix formulation comprising 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da pripravak sadrži najmanje oko 80 % (težinski) polietilen oksida koji ima, prema reološkim mjerenjima, približnu molekularnu težinu od najmanje 1,000,000.
the second antibody is an anti-IGF1R antibody, an anti-EGFR antibody, or an anti-cmet antibody; or the agent is an antimetabolite, an alkylating agent, a topoisomerase inhibitor, a microtubule-targeting agent, a kinase inhibitor, a protein synthesis inhibitor, an immunotherapeutic, a hormone or analog thereof, a somatostatin analog, a glucocortocoid, an aromatose inhibitor, an mTOR inhibitor, a small molecule targeting IGF1R, or a small molecule targeting EGFR. 
(a) drugo antitijelo je anti-IGFIR antitijelo, anti-EGFR antitelo ili anti-cmet antitijelo; ili (b) sredstvo je antimetabolit, alkirajuće sredstvo, inhibitor topoizomerase, sredstvo sa ciljanim djelovanjem na mikrotubule, inhibitor kinaze, inhibitor sinteze proteina, imunoterapeutik, hormon ili njegov analog, analog somatostatina, glukokortokoid, inhibitor aromatoze, inhibitor mTOR, mala molekula koja ciljano djeluje na IGFIR ili mala molekula koja ciljano djeluje na EGFR.
The crystalline form of claim 1, wherein the crystalline form is selected from the group consisting of: 
supstituirani pripojeni dvostruki heterociklilni prsten je odabran iz skupine koja sadrži [image] [image]
A lipid particle of claim 7 for use in a method for the in vivo delivery of a therapeutic agent, wherein the administration of said lipid particle is selected from the group consisting of oral, intranasal, intravenous, intraperitoneal, intramuscular, intra-articular, intralesional, intratracheal, subcutaneous, and intradermal. 
Čestica lipida za uporabu u skladu s patentnim zahtjevom 13, naznačena time, da je primjena odabrana iz skupine koju čine oralni, intranazalni, intravenski, intraperitonealni, intramuskularni, intraartikularni, intralezionalni, intratrahealni, subkutani i intradermalni.
which is used to treat a side effect of cancer or viral infection, preferably wherein the side effect is fatigue or weight loss. 
koje se koristi za liječenje nuspojava raka ili virusne infekcije.
a circuit (TR) for receiving phase relation information (M1); 
- < krug(TR) za primanje informacije faznog odnosa (M1);
The method according to any of claims 24-26, wherein in step (a), the binder is hydroxypropyl cellulose SSL; in step (e), the filler is microcrystalline cellulose and the disintegrant is sodium starch glycolate; and in step (f), the lubricant is magnesium stearate. 
Postupak prema bilo kojem od zahtjeva 24-26, naznačen time što u koraku (a), vezivo je hidroksipropil celuloza SSL; u koraku (e), punilo je mikrokristalna celuloza i sredstvo za raspadanje je natrijev škrob glikolat; i u koraku (f), sredstvo za povećanje skliskosti je magnezijev stearat.
iii) C3-6cycloalkyl optionally substituted with one to two fluoro substituents; 
i pri čemu je navedeni pirazolil opciono supstituiran sa jednim metil supstituentom;
The pharmaceutically acceptable liquid composition of claim 1 or 2, wherein said pharmaceutically acceptable salt of ascorbic acid is ascorbate, Na-ascorbate, calcium ascorbate, potassium ascorbate, ascorbyl palmitate, or ascorbyl stearate. 
Farmaceutski prihvatljivi tekući pripravak u skladu s patentnim zahtjevom 5, naznačen time što je navedena farmaceutski prihvatljiva sol askorbinske kiseline askorbat, Na-askorbat, kalcijev askorbat, kalijev askorbat, askorbil-palmitat, ili askorbil-stearat.
A compound of formula Ia: or a pharmaceutically acceptable salt thereof for use with one or more agents selected from 5-FU, capecitabine, or a pharmaceutically acceptable salt thereof, in the therapeutic treatment of a hyperproliferative disorder. 
Spoj, naznačen time, da ima formulu Ia: [image] te se u kombinaciji s abirateronom upotrebljava u terapeutskom postupku liječenja hiperproliferativnog poremećaja, pri čemu se kod hiperproliferativnog poremećaja radi o raku prostate.
The pharmaceutical composition for use according to claim 5 or 6, comprising additional 5-HT7-active components selected from the group comprising aripiprazole, amisulpride, chlorpromazine, clozapine, risperidone, ziprasidone, fluoxetine, 5-CT, 5-methoxytryptamine, 8-OH-DPAT, aripiprazole, AS-19, E-55888, MSD-5a, LP-12, LP-44, LP-211, RA-7, and Nw -methylserotonin. 
Farmaceutski pripravak za uporabu prema zahtjevu 5 ili 6, naznačen time što sadrži dodatne 5-HT7- aktivne komponente odabrane iz skupine koja sadrži aripiprazol, amisulprid, klorpromazin, klozapin, risperidon, ziprasidon, fluoksetin, 5-CT, 5-metoksitriptamin, 8 -OH-DPAT, aripiprazol, AS-19, E-55888, MSD-5a, LP-12, LP-44, LP-211, RA-7 i Nw-metilserotonin.
extruding a base film comprising a stretchable polyolefin material comprising one or more layers; extruding a plurality of fibre elements; 
(i) ekstrudiranje osnovne folije koja obuhvaća rastezljivi poliolefinski materijal koji obuhvaća jedan 1l1 više slojeva; (11) ekstrudiranje više elemenata vlakana;
The method according to item 13, wherein color pigments (13) are applied in a separate step in dry form and bonded by the water based drops. 
Metoda u skladu sa patentnim zahtjevom 12, gdje su pigmenti boje (13) naneseni u odvojenom koraku u suhom obliku i spojeni kapima koje su u osnovi voda.
The method as claimed in claim 10, wherein sensing the position and voice identity pertaining to each individual speaker comprises employing a plurality of sound sensors and at least one sound location sensor, and wherein at least one of the sound sensors is a microphone. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što se detektiranje položaja 1 identiteta glasa svakog pojedinačnog govornika (16) sastoji u upotrebi više senzora zvuka i najmanje jednog senzora položaja zvuka (22), te što što je najmanje jedan od senzora zvuka mikrofon (20).
The system according to claim 1, wherein said plants of the line are track circuits, light-signalling devices, vital inputs/outputs) drive boxes, etc. 
Sustav u skladu s patentnim zahtjevom 1, naznačen time što su navedene linije opreme krugovi za detektiranje prekida napajanja, uređaji svjetlosne signalizacije, vitalni ulazi/izlazi, pogonske kutije itd.